2023
DOI: 10.1093/ndt/gfad058
|View full text |Cite
|
Sign up to set email alerts
|

Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 11 publications
0
1
0
Order By: Relevance
“…Cho et al. 31 reported that only 27 patients with advanced CKD and kidney failure were treated in the first 10 months since the emergency use authorization. Our findings, in conjunction with the ongoing clinical trial (Phase I: NCT05487040 ), can help fill a critical knowledge gap regarding the effectiveness of oral antivirals in the CKD population.…”
Section: Discussionmentioning
confidence: 99%
“…Cho et al. 31 reported that only 27 patients with advanced CKD and kidney failure were treated in the first 10 months since the emergency use authorization. Our findings, in conjunction with the ongoing clinical trial (Phase I: NCT05487040 ), can help fill a critical knowledge gap regarding the effectiveness of oral antivirals in the CKD population.…”
Section: Discussionmentioning
confidence: 99%